CanSino Biologics is a biotechnology company dedicated to the R&D, manufacturing, and commercialization of vaccine products for human use. CanSino’s mission is to develop high-value and high-quality vaccines for China and other emerging countries at an affordable cost. Equipped with cutting-edge scientific know-how and technology, CanSino’s goal is to lead and foster the Chinese vaccine industry into a major contributor to global public health.
|Employees (est.) (May 2017)||166,741|
CanSino Biologics total Funding
CanSino Biologics latest funding size
Time since last funding
|3 years ago|
CanSino Biologics investors
|GoldStone, Qiming Venture Partners, Fortune Capital, Gopher Asset Management, Lilly Asia Ventures, Future Industry Investment Fund|
When was CanSino Biologics founded?
CanSino Biologics was founded in 2009.
How many employees does CanSino Biologics have?
CanSino Biologics has 166,741 employees.
Who are CanSino Biologics competitors?
Competitors of CanSino Biologics include AstraZeneca, Molecular Templates and Lineage Cell Therapeutics.
Receive alerts for 300+ data fields across thousands of companies